Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Aggression × Rituximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 213 Lymphoma, Non-Hodgkin 169 Leukemia, Lymphocytic, Chronic, B-Cell 159 Lymphoma, Large B-Cell, Diffuse 147 Lymphoma, Follicular 138 Lymphoma, Mantle-Cell 103 Leukemia 70 Lymphoma, B-Cell, Marginal Zone 64 Waldenstrom Macroglobulinemia 45 Burkitt Lymphoma 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 40 Lymphoma, Large-Cell, Immunoblastic 35 Lymphoma, B-Cell 34 Hodgkin Disease 34 Recurrence 27 Multiple Myeloma 14 Myelodysplastic Syndromes 12 Hematologic Neoplasms 12 Neoplasms 10 Lymphoma, Large-Cell, Anaplastic 10 Leukemia, Myeloid, Acute 10 Dendritic Cell Sarcoma, Interdigitating 8 Lymphoma, T-Cell 6 Leukemia, Prolymphocytic 6 Neoplasms, Plasma Cell 5 Leukemia, B-Cell 5 Intraocular Lymphoma 5 Myeloproliferative Disorders 4 Myasthenia Gravis 4 Lymphoma, AIDS-Related 4

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 Topotecan 1 Rituximab 1 Prednisone 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡